Anesthetic and Analgesic Effect of Neostigmine when Added to Lidocaine in Intravenous Regional Anesthesia

Alaa Mohammed Atia and Khaled Abdel-Baqy Abdel-Rahman

Department of Anesthesia and Intensive Care, Faculty of Medicine, Assiut University, Egypt

Corresponding author: Alaa M Atia, Department of Anesthesia and Intensive Care, Faculty of Medicine, Assiut University, Egypt, Tel: 0201223591937; E-mail: alaa.guhina@yahoo.com

Received date: July 18, 2016; Accepted date: August 25, 2016; Published date: August 31, 2016

Abstract

Background: Intravenous regional anesthesia (IVRA) has various advantages during short surgical procedures in upper and lower limbs, but one of its disadvantages is minimal postoperative pain relief.

Aim of the study: To evaluate the anesthetic and analgesic effect of adding 1 mg neostigmine to 0.5% lidocaine in IVRA.

Patients and methods: This randomized double blind controlled clinical trial was carried out at Assiut University Hospital after the approval of its Ethical committee and after obtaining an informed consent from all the patients. Eighty ASA I or II patients who were scheduled for elective hand and forearm surgery were included. We excluded patients with chronic pain syndrome, Reynaud disease, sickle cell anemia, diabetes, pregnancy, lactation, drug allergy and psychological disorders. Patients were randomly assigned to control group who received 3 mg/kg 0.5% lidocaine plus 1 ml normal saline in 40 ml volume and neostigmine group who received 3 mg/kg 0.5% lidocaine plus 1 mg neostigmine in 40 ml volume. Patients were assessed for onset and recovery from the sensory and motor blocks, postoperative pain, analgesic request and incidence of complications. Results No statistically significant differences were observed between groups as regards demographic data, anesthetic or analgesic criteria or the incidence of complications.

Conclusion: Addition of 1 mg neostigmine to 0.5% lidocaine in IVRA has no anesthetic or analgesic effect, and there is no increase in the incidence of complications. There are no biological facts that support its use as adjuvant to local anesthetic agents in IVRA.

Keywords: Neostigmine; Lidocaine; Intravenous regional anesthesia; Analgesic effect; Anesthetic

Introduction

Intravenous regional anesthesia (IVRA) was first introduced by Karl August Bier in 1908 [1]. IVRA is considered as an easy technique with high success rate [2] and low cost suitable for short operative procedures in upper and lower limbs [3].

IVRA has also some disadvantages which include administration of high dose of local anesthetic, poor muscle relaxation, slow onset, tourniquet pain, nerve injuries, compartment syndrome, widespread petechial, skin discoloration and minimal postoperative pain relief [4,5]. Various adjuvant drugs have been evaluated in conjunction with LA to improve IVRA block with variable results [2].

Neostigmine is a typical cholinesterase inhibitor. It increases the level of acetylcholine (Ach) and indirectly stimulates both nicotinic and muscarinic receptors. In anesthesia neostigmine is a drug that has been used for reversal of residual neuromuscular block. Administration of neostigmine by intrathecal and epidural routes has been found to cause analgesia by inhibition of the breakdown of Ach in the spinal cord [6,7]. Some recent studies did not find significant effects in peripheral nerve blocks and IVRA [8,9].

This study was designed to evaluate the anesthetic and analgesic effects of adding 1 mg neostigmine to 0.5% lidocaine in IVRA.

Methods

This randomized double blind controlled clinical trial was carried out at Assiut University Hospital after approval of its Ethical committee and obtaining informed consents from all patients.

We included eighty unsedated ASA physical status I or II between 25 and 60 years of age who were scheduled for elective hand and forearm surgery with estimated time of surgery of less than 1 hour. We excluded patients with chronic pain syndrome, Reynaud disease, sickle cell anemia, diabetes, pregnancy, lactation, drug allergy and psychological disorders. Patients were randomly assigned using computer generated random numbers into one of two groups: The control group (group C, n=40) received 3 mg/kg 0.5% lidocaine plus 1 ml normal saline while the neostigmine group (group N, n=40), received 3 mg/kg 0.5% lidocaine plus 1 mg neostigmine. The study drugs were made to volume of 40 ml for both groups to avoid bias.

An intravenous line was placed into the dorsum of the hand to be operated upon for injection of the study drugs. A second IV line was placed into the other upper limb for fluids and emergency drugs administration. Patients were monitored with ECG, pulse oximetry and noninvasive blood pressure. Following exsanguination of the arm
by its elevation for 1-3 minutes and wrapping Esmarch bandage, a pneumatic cuff was applied around the upper third of the arm and inflated to at least 100 mmHg above the patient’s systolic pressure and the Esmarch bandage was removed, 40 ml of the study drug was then injected over one minute. When anesthesia was established, a second distal tourniquet was applied and inflated followed by release of the proximal one. At the end of surgery and after at least half an hour of intravenous local anesthetic injection the tourniquet was gradually deflated and all patients were transferred to the post anesthesia care unit. Intraoperative and postoperative bradycardia defined as heart rate <50 beat/min was treated with 0.5 mg intravenous atropine and/or intravenous 10 mg ephedrine. Pressure <40% of the baseline was treated with intravenous fluids and/or intravenous 10 mg ephedrine.

Patients assessed their pain using visual analogue scale (on 10 points scale, 0-10) at half an hour interval. Patients whose pain score exceeds 3 were given 30 mg ketorolac and such was repeated on patient request. Intractable pain was managed with pethidine 100 mg IM. The onset of sensory block was assessed every minute with 22 gauge short beveled needle for pinprick and a piece of cotton for touch. The motor function was assessed by asking the patient to flex and extend his fingers and wrist. A complete motor block was defined as inability to move fingers voluntarily. The degree of tourniquet and hand pain was assessed using visual analogue scale (VAS). The duration of sensory and motor block after tourniquet release was determined by restoration of normal surface sensation and motor recovery as compared with the other sound limb. Any complication during surgery and after deflation of the tourniquet (such as nausea, vomiting, dyspnea, bradycardia, dizziness, or hypotension) was also recorded.

Statistical analysis

Data were expressed as mean ± SD unless otherwise indicated. Data were analyzed using fisher’s exact t-tests and Mann Whitney test as appropriate. P-value <0.05 was considered statistically significant.

Results

Eighty patients were included in the study and were equally distributed among the two groups. There were no differences in the demographic data (age, weight, sex), duration of surgery and tourniquet time between both groups (Table 1). There was no significant difference in the onset of pinprick loss, touch loss and motor block between both groups (Table 2).

No significant differences were also observed in the pinprick, touch and motor block recovery after tourniquet deflation between both groups (Table 2).

At the time of admission in to the recovery room, we did not observe statistically significant difference in VAS score between both groups. Also no significant differences were observed between both groups as regards time to first analgesic request, the total dose of ketorolac used or the number of patients needing supplemental opioid (Table 3).

In addition, no significant differences in postoperative complications were observed between both groups (Table 4).

Table 1: Demographic and surgical data.

|                      | Group C (n=40) | Group N (n=40) | P-value |
|----------------------|---------------|---------------|---------|
| Age (yr)             | 44.9 ± 13.3   | 45.3 ± 12.1   | 0.861   |
| Sex (M/F)            | 32/8          | 29/12         | 0.439   |
| Weight (kg)          | 76.4 ± 11.5   | 73.4 ± 13.1   | 0.281   |
| ASA (I/II)           | 31/9          | 27/13         | 0.453   |
| Surgical duration (min) | 33.2 ± 8.4 | 35.9 ± 12.1   | 0.251   |
| Tourniquet time (min) | 47.7 ± 6.7   | 50.4 ± 12.1   | 0.254   |

Data were represented as mean ± SD unless otherwise indicated

Table 2: Onset and recovery from sensory and motor block (min).

|                          | Group C (n=40) | Group N (n=40) | P-value |
|--------------------------|---------------|---------------|---------|
| Pinprick onset time (min)| 7.3 ± 0.4     | 7.5 ± 0.4     | 0.128   |
| Touch onset time (min)   | 10.2 ± 0.5    | 10.4 ± 0.7    | 0.235   |
| Motor block onset time (min) | 14.9 ± 1.5  | 15.1 ± 1.4    | 0.55    |
| Pinprick recovery time (min) | 4.0 ± 0.9    | 3.8 ± 1.0     | 0.287   |
| Touch recovery time (min) | 3.7 ± 1.2     | 3.4 ± 0.9     | 0.251   |
| Motor block recovery time (min) | 2.1 ± 0.6    | 1.9 ± 0.5     | 0.266   |

Data were represented as mean ± SD

Table 3: VAS in the recovery room and the time of 1st analgesic requirement.

|                          | Group C (n=40) | Group N (n=40) | P-value |
|--------------------------|---------------|---------------|---------|
| VAS on admission to the recovery room | 4.4 ± 1.4 | 4.1 ± 1.2 | 0.401 |
| Time to 1st analgesic requirement (min) | 25.3 ± 6.7 | 26.9 ± 7.3 | 0.334 |
| Total ketorolac consumption (mg) | 58.5 ± 23.5 | 61.5 ± 19.2 | 0.533 |
| Patients in need of pethidine (No. (%)) | 5 (13%) | 3 (8%) | 0.712 |

Data were represented as mean ± SD and number (%)

Table 4: Postoperative complications No. (%).
Discussion

The results of this study showed no significant differences between both groups in terms of gender, body weight, height, ASA status, type and duration of surgery and the tourniquet time. The study results also showed no statistically significant difference in both the onset of sensory and motor blocks; and the time to sensory and motor recovery in the two study groups.

Many studies on the analgesic efficacy of neostigmine in IVRA gave different results. Neostigmine has been used with different local anesthetic agents and in different doses. Turan et al. [10] in 2002 found that addition of 0.5 neostigmine to prilocaine causes shortened sensory and motor block onset, prolonged sensory and motor block recovery, improved quality of anesthesia and prolonged time to first analgesic request. The study by Turan et al. was in agreement with the results obtained by Marashi et al. [11] and Sethi et al. [12] in which 0.5 % lidocaine was used instead of prilocaine. Kang et al. [13] used ropivacaine and observed good outcome with 0.5 mg of neostigmine as an adjunct.

In contrary to our results, McCartney et al. [9] found no analgesic benefits of 1 mg neostigmine when added to 0.5% lidocaine. Kuyrukluyildiz et al. also did not find analgesic effect of neostigmine when compared to control group [14].

Evidences for analgesic effects of neostigmine are more with its intrathecal and epidural administration. The increased concentration of Ach binds to the muscarinic receptors [15] placed in the dorsal horn cells, substantia gelatinoza and lamina III and V of the spinal cord [16] and nicotinic receptors [17-19] placed in the descending noradrenergic fibers [18], dorsal root ganglion [20] and in microganglia [19]. The presence of cholinergic activity seems to be an important condition for neostigmine analgesic effect [21,22] which could be reversed by muscarinic receptor antagonists [23]. Although Day et al. [24] suggests that Ach receptors exists in peripheral nerve endings, it seems that strong evidences are lacking for this mechanism in the periphery.

The mechanism of action of IVRA itself is still unclear [25], some authors suggest nerve trunk as the main site of action of local anesthetics [26,27], while others suggest peripheral sites to be the main site of action [28,29]. In both cases, the presence of blood-nerve barrier at the innermost layer of perineurium and at the endothelial microvasculature [30] with its highly specialized characteristics as “barrier forming cells” [31] may prevent the transport of neostigmine (a quaternary ammonium compound) to the site of action with the main local anesthetic.

In conclusion, we found that addition of 1 mg neostigmine to 0.5% lidocaine in IVRA has no anesthetic or analgesic effect and there is no increase in the incidence of complications. We did not find any biological fact that supports the use of neostigmine as adjuvant to local anesthetic agents in IVRA.

References

1. Bier A (1908) A new method for local anaesthesia in the extremities. Ann Surg 48: 780.
2. Choyce A, Peng P (2002) A systematic review of adjuncts for intravenous regional anesthesia for surgical procedures. Can J Anaesth 49: 32-45.
3. Chan VW, Peng PWH, Kaszas Z, Middleton WJ, Muni R, et al. (2001) A comparative study of general anesthesia, intravenous regional anesthesia, and axillary block for outpatient hand surgery: clinical outcome and cost analysis. Anesth Analg 93: 1181-1184.
4. Brown EM, McGriff JT, Malinowski RW (1989) Intravenous regional anesthesia (Bier block): review of 20 years’ experience. Can J Anaesth 36: 307-310.
5. Guay J (2009) Adverse events associated with intravenous regional anesthesia (Bier block): a systematic review of complications. J Clin Anesth 21: 585-594.
6. Naguib M, Yakh TL (1994) Antinociceptive Effects of Spinal Cholinesterase Inhibition and Isobolographic Analysis of the Interaction with a α and α Receptor Systems. Anesthesiology 80: 1338-1348.
7. Lauretti GR, Reis MP, Prado WA, Klamt JG (1996) Dose-response study of intrathecal morphine versus intrathecal neostigmine, their combination, or placebo for postoperative analgesia in patients undergoing anterior and posterior vaginoplasty. Anesth Analg 82: 1182-1187.
8. Van Elstraete AC, Pastureau F, Lebrun T, Mehdouai H (2001) Neostigmine added to lidocaine as adjunct for local anesthesia using a Luer-lock block for postoperative analgesia. Eur J Anaesthesiol 18: 257-260.
9. McCartney CJ, Brill S, Rawson R, Sanandaji K, Lagounova A, et al. (2003) No anesthetic or analgesic benefit of neostigmine 1 mg added to intravenous regional anesthesia with lidocaine 0.5% for hand surgery. Reg Anesth Pain Med 28: 414-417.
10. Turan A, Karamanlıoğlu B, Memis D, Kaya G, Pamukçu Z (2002) Intravenous regional anesthesia using prilocaine and neostigmine. Anesth Analg 95: 1419-1422.
11. Marashi SM, Yazdanifard S, Shoebi G, Bakhshandeh H, Yazdanifard P, et al. (2008) The analgesic effect of intravenous neostigmine and transdermal nitroglycerine added to lidocaine on intravenous regional analgesia (Bier’s block): a randomized, controlled study in hand surgery. International Journal of Pharmacology 4: 218-222.
12. Sethi D, Wason R (2010) Intravenous regional analgesia using lidocaine and neostigmine for upper limb surgery. J Clin Anesth 22: 324-328.
13. Kang KS, Jung SH, Ahn KR, Kim CS, Kim JE, et al. (2004) The effects of neostigmine added to ropivacaine for intravenous regional anesthesia. Korean Journal of Anesthesiology 46: 649-654.
14. Kuyrukluyildiz U, Kolтика N, Ozcekic AN, Sarar S, Celik M, et al. (2008) Addition of Dexametomidine or Neostigmine to Lidocaine for Intravenous Regional Analgesia: 379. Regional Anesthesia and Pain Medicine 33: e81.
15. Honda K, Harada A, Takano Y, Kamiya H (2000) Involvement of M3 muscarinic receptors of the spinal cord in formalin-induced nociception in mice. Brain Res 859: 38-44.
16. Wamsley JK, Lewis MS, Young WS 3rd, Kuhar MJ (1981) Autoradiographic localization of muscarinic cholinergic receptors in rat brainstem, J Neurosci 1: 176-191.
17. Duttaroy A, Gomeza J, Gan JW, Siddiqui N, Basile AS, et al. (2002) Evaluation of muscarinic agonist-induced analgesia in muscarinic acetylcholine receptor knockout mice. Mol Pharmacol 62: 1084-1093.
18. Vincler M, Eisenach JC (2004) Plasticity of spinal nicotinic acetylcholine receptors following spinal nerve ligation. Neuroscience research 48: 139-145.
19. Thomsen MS, Mikkelsen JD (2012) The a7 nicotinic acetylcholine receptor ligands methyllycaconitine, NS6740 and GTS-21 reduce lipopolysaccharide-induced TNF-a release from microglia. Journal of neuroimmunology 251: 65-72.
20. Genzen JR, Van Cleve W, McGehee DS (2001) Dorsal root ganglion neurons express multiple nicotinic acetylcholine receptor subtypes. Journal of Neurophysiology 86: 1773-1782.
21. Bouaziz H, Tong C, Eisenach JC (1995) Postoperative analgesia from intrathecal neostigmine in sheep. Anesthesia & Analgesia 85: 1140-1144.
22. Zhuo M, Gebhart GF (1991) Tonic cholinergic inhibition of spinal neuroimmunology 251: 65-72.
23. Naguib M, Yakh TL (1997) Characterization of muscarinic receptor subtypes that mediate antinociception in the rat spinal cord. Anesthesia & Analgesia 85: 847-853.
24. Day NS, Berti-Mattera LN, Eichberg J (1991) Muscarinic cholinergic receptor-mediated phosphoinositide metabolism in peripheral nerve. J Neurochem 56: 1905-1913.

25. Brill S, Middleton W, Brill G, Fisher A (2004) Bier’s block; 100 years old and still going strong! Acta Anaesthesiol Scand 48: 117-122.

26. Raj PP (1972) The site of action of intravenous regional anesthesia. Anesthesia & Analgesia 51: 776-786.

27. Risdall J (1997) A comparison of intercuff and single cuff techniques of intravenous regional anaesthesia using 0.5% prilocaine mixed with technetium 99m-labelled BRIDA. Anaesthesia 52: 842-848.

28. Haasio J, Hiippala S, Rosenberg PH (1989) Intravenous regional anaesthesia of the arm. Effect of the technique of exsanguination on the quality of anaesthesia and prilocaine plasma concentrations. Anaesthesia 44: 19-21.

29. Moore DC (1984) Bupivacaine toxicity and Bier block: the drug, the technique, or the anesthetist. Anesthesiology 61: 782.

30. Bell MA (1984) A descriptive study of the blood vessels of the sciatic nerve in the rat, man and other mammals. Brain 107: 871-898.

31. Sano Y, Shimizu F, Nakayama H, Abe M, Maeda T, et al. (2007) Endothelial cells constituting blood-nerve barrier have highly specialized characteristics as barrier-forming cells. Cell structure and function 32: 139-147.